Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Balancing Cost Savings With Clinical Practice for Multiple Myeloma Biosimilars: Tyler Sandahl, PharmD

July 14th 2025

By Cameron Santoro

Article

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges adopting an intravenous daratumumab biosimilar, preferring the more convenient subcutaneous option.

Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems

July 11th 2025

By Aislinn Antrim

Article

The Top 5 Biosimilar Articles for the Week of July 7

July 11th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of July 7, 2025.

Two More Pairs of Denosumab Biosimilars Enter US Market

July 9th 2025

By Skylar Jeremias

Article

The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and bone-related metastases.

Dispelling Doubts: Review Affirms Safety, Efficacy of Biosimilar Insulins

July 8th 2025

By Skylar Jeremias

Article

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for diabetes treatment.

Consumers and Providers Face Biosimilar Knowledge Hurdles

July 7th 2025

By Skylar Jeremias

Article

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption and potential benefits in health care.

Australian Patients With IBD Switched to Biosimilar Infliximab Maintain Long-Term Persistence

July 5th 2025

By Deana Ferreri, PhD

Article

Long-term data from the SAME study confirm that switching to infliximab biosimilars is safe and effective for patients with inflammatory bowel disease (IBD).

The Top 5 Biosimilar Articles for the Week of June 30

July 4th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of June 30, 2025.

Biosimilar SB12 Matches Eculizumab in PNH Treatment Across Diverse Patient Groups

July 3rd 2025

By Cameron Santoro

Article

Biosimilar SB12 demonstrated comparable efficacy and safety for paroxysmal nocturnal hemoglobinuria (PNH) to its reference drug, showing similar outcomes across diverse patient groups.

Real-World Data Suggest Long-Term Safety of CT-P13 in IBD, RA

July 2nd 2025

By Deana Ferreri, PhD

Article

The MEGA-J study reveals CT-P13's long-term safety and effectiveness in treating inflammatory bowel disease and rheumatoid arthritis, with minimal adverse reactions.